Filter by: Subject

Filter by: Subject

Results Per Page:

Computed tomography (CT) (2)
Hypoxia (2)
Immunohistochemistry (2)
Metastatic castration-resistant prostate cancer (mCRPC) (2)
Somatropin (2)
Therapy response (2)
Tuberculosis (TB) (2)
18F-FDG (1)
225Ac-PSMA (1)
68Ga-citrate (1)
68Ga-Nitroimidazole (1)
[68Ga]Ga-FAPI PET/CT (1)
Androgen deprivation treatment (ADT) (1)
Angiogenesis (1)
Behandlung (1)
Benign vs. malignant (1)
Bins (1)
Bioassay (1)
Biomaterials (1)
Black South-African (BSAs) (1)
Blood–brain barrier (BBB) (1)
Bone SPECT-CT (1)
Capillary electrophoresis–mass spectrometry (CE-MS) (1)
Characterization (1)
Chelation (1)
Chemical analysis (1)
Chemical modification (1)
Chromatography (1)
Colon cancer (1)
Colorectal cancer (1)
Computerized tomography (CT) (1)
Computerized tomography' (CT) (1)
Cryptic peptides (1)
Dichroism (1)
Drug products (1)
FAPI tumor volume (FAPI-TV) (1)
FDG PET/CT (1)
FDG-PET (1)
FDG-PET imaging (1)
Fludeoxyglucose (FDG) (1)
Fluorine-18-Fluorodeoxyglucose (FDG) (1)
Fluorodeoxyglucose-positron emission tomography (FDG PET) (1)
Functional characterization (1)
Gastro-intestinal cancer (1)
GHR bioassay (1)
Growth hormone receptor (GHR) (1)
Highly active antiretroviral therapy (HAART) (1)
HIV infection (1)
Human growth hormone (1)
Human microbiome (1)
Hypoxia inducible factor-1 (HIF-1) (1)
Hypoxia-inducible factor-1alpha (HIF-1) (1)
Hypoxic tumor volume (HTV) (1)
Immunohistochemistry (IHC) (1)
Inherent complexity (1)
Intra-tumoral heterogeneity (1)
Isomers (1)
Lipodystrophy (1)
Liquid chromatography–mass spectrometry (LC-MS) (1)
Logistic binomial regression (1)
Loosening (1)
Lumbar fusion (1)
Lung lesions (1)
Mass spectrometry (1)
Medical imaging (1)
Metabolic tumor volume (MTV) (1)
Metastasis (1)
Metastatic hormone-sensitive prostate carcinoma (mHSPC) (1)
Metastatic prostate carcinoma (1)
Microbiome (1)
Multiple substitutions (1)
Native mass spectrometries (1)
Native MS (1)
Non-prostate carcinoma (1)
NOTA modification (1)
Ovarian cancer (1)
Overall survival (OS) (1)
Patient management (1)
Patienten management (1)
Pedicle screws (1)
Peptide mapping (1)
Physico-chemical characterization (1)
Positron emission tomography/computed tomography (PET/CT) (1)
Prevention (1)
Primary prostate carcinoma (PPC) (1)
Principal component analysis (PCA) (1)
Progression-free survival (PFS) (1)
Prostate specific antigen (PSA) (1)
Prostate specific membrane antigen (PSMA) (1)
Proteins (1)
Pulmonary (1)
Quality control (1)
Quorum sensing peptides (1)
Racial differences (1)
Radioligand therapy (1)
Radiomics (1)
Recombinant human growth hormones (1)
Serum tumor markers (1)
Signal transduction (1)
Single photon emission computed tomography (SPECT) (1)